NYSE: NVO - Novo Nordisk A/S

Yield per half year: -45.06%
Dividend yield: +1.76%
Sector: Healthcare

Share chart Novo Nordisk A/S


About Novo Nordisk A/S

Novo Nordisk A/S, медицинская компания, занимается исследованиями, разработками, производством и маркетингом фармацевтической продукции по всему миру. Он работает в двух сегментах: лечение диабета и ожирения и биофармация. Сегмент лечения диабета и ожирения предоставляет продукты в области инсулинов, GLP-1 и родственных систем доставки, пероральных противодиабетических продуктов, ожирения и других хронических заболеваний. Сегмент биофармацевтических препаратов предлагает продукты для лечения гемофилии, нарушений роста и заместительной гормональной терапии.

more details
Соглашения о сотрудничестве компании с Gilead Sciences, Inc. Novo Nordisk A/S также сотрудничает в исследованиях с Lumen Bioscience, Inc. для изучения стратегий доставки пероральных биопрепаратов для лечения кардиометаболических заболеваний. Компания была основана в 1923 году и имеет штаб-квартиру в Багсверде, Дания.

IPO date 1982-01-04
ISIN US6701002056
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета dkk
Див.доход ао 2.49
Дивиденд ао 1.1
Сайт https://www.novonordisk.com
Цена ао 71.73
Change price per day: 0% (64.73)
Change price per week: +1.71% (63.64)
Change price per month: -14.71% (75.89)
Change price per 3 month: -23.51% (84.62)
Change price per half year: -45.06% (117.81)
Change price per year: -47.57% (123.45)
Change price per 3 year: -43.08% (113.72)
Change price per 5 year: +8.26% (59.79)
Change price per year to date: -24.5% (85.73)

Underestimation

Title Value Grade
P/S 9.44 1
P/BV 19.1 1
P/E 27.13 6
EV/EBITDA 20.58 5
Total: 5.5

Efficiency

Title Value Grade
ROA, % 25.89 8
ROE, % 80.78 10
Total: 9.5

Dividends

Title Value Grade
Div yield, % 1.76 4.4
DSI 0.9286 9.29
Total: 4.93

Debt

Title Value Grade
Debt/EBITDA 0.7482 9
Total: 8.4

Growth impulse

Title Value Grade
Yield Revenue, % 128.76 10
Yield Ebitda, % 128.14 10
Yield EPS, % 1524.49 10
Total: 10

Institutions Volume Share, %
Jennison Associates LLC 22527772 0.66
Fisher Asset Management, LLC 14129598 0.41
Renaissance Technologies, LLC 13849335 0.4
Bank of America Corporation 12975409 0.38
FMR, LLC 12663225 0.37
Sarofim, Fayez & Co 11814051 0.34
Morgan Stanley 10614811 0.31
Loomis Sayles & Company, LP 9003325 0.26
Folketrygdfondet 8631264 0.25
Polen Capital Management, LLC 7958444 0.23

ETFShare, %Profitability for 1 year, %Dividends, %
Fidelity Growth Opportunities ETF 0.45018 -9.28 0.48881
Fidelity New Millennium ETF 0.32428 -5.13 1.58241
0.39-7.211.03



Head Job title Payment Year of birth
Mr. Lars Fruergaard Jorgensen President, CEO & Member of Management Board 4.67M 1966 (59 years)
Mr. Karsten Munk Knudsen Executive VP, CFO & Member of the Management Board 1.85M 1971 (54 years)
Mr. Henrik Ehlers Wulff Executive VP of Product Supply, Quality & IT and Member of the Management Board 1.87M 1970 (55 years)
Ms. Camilla Sylvest Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board 1.82M 1972 (53 years)
Mr. Maziar Mike Doustdar Executive VP of International Operations & Member of the Management Board N/A 1970 (55 years)
Mr. Douglas J. Langa Executive VP of North America Operations & Member of Management Board N/A 1966 (59 years)
Mr. Ludovic Helfgott Executive VP, Head of Rare Disease & Member of Management Board N/A 1974 (51 year)
Dr. Martin Holst Lange Executive VP of Development & Member of the Management Board 1.77M 1970 (55 years)
Dr. Marcus Schindler Ph.D. EVP of Research & Early Development, Chief Scientific Officer & Member of the Management Board 1.77M 1966 (59 years)
Ms. Tania Sabroe Executive VP of Global People & Organisation and Member of Management Board N/A 1977 (48 years)

Address: Denmark, Bagsvaerd, Novo Alle 1 - open in Google maps, open in Yandex maps
Website: https://www.novonordisk.com